Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

EQS-News: Heidelberg Pharma’s Partner Telix Reports Positive Data on the Pivotal ZIRCON Study
EQS-News: Heidelberg Pharma’s Partner Telix Reports Positive Data on the Pivotal ZIRCON Study
EQS-News: Heidelberg Pharma’s Partner Telix Reports Positive Data on the Pivotal ZIRCON Study
eqs_en 
0 07.11.22
EQS-News: Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2022
EQS-News: Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2022
EQS-News: Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2022
eqs_en 
0 13.10.22
EQS-Adhoc: Heidelberg Pharma AG Announces Adjustment of Guidance
EQS-Adhoc: Heidelberg Pharma AG Announces Adjustment of Guidance
EQS-Adhoc: Heidelberg Pharma AG Announces Adjustment of Guidance
eqs_en 
0 04.10.22
EQS-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports H1 2022 Financial Results and Highlights Operational Progress
EQS-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports H1 2022 Financial Results and Highlights Operational Progress
EQS-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports H1 2022 Financial Results and Highlights Operational Progress
eqs_en 
0 30.09.22
EQS-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Announces Successful Private Placement of up to EUR 30 Million
EQS-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Announces Successful Private Placement of up to EUR 30 Million
EQS-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Announces Successful Private Placement of up to EUR 30 Million
eqs_en 
0 30.09.22
EQS-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report H1 2022 Financial Results and Operational Progress on September 30, 2022
EQS-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report H1 2022 Financial Results and Operational Progress on September 30, 2022
EQS-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report H1 2022 Financial Results and Operational Progress on September 30, 2022
eqs_en 
0 26.09.22
DGAP-Adhoc: Heidelberg Pharma Announces Conclusion of License Agreement with Partner Takeda To Develop an Antibody Targeted Amanitin Conjugate
DGAP-Adhoc: Heidelberg Pharma Announces Conclusion of License Agreement with Partner Takeda To Develop an Antibody Targeted Amanitin Conjugate
DGAP-Adhoc: Heidelberg Pharma Announces Conclusion of License Agreement with Partner Takeda To Develop an Antibody Targeted Amanitin Conjugate
eqs_en 
0 09.09.22
DGAP-News: Heidelberg Pharma AG Raises Approximately EUR 80 Million From Capital Measure
DGAP-News: Heidelberg Pharma AG Raises Approximately EUR 80 Million From Capital Measure
DGAP-News: Heidelberg Pharma AG Raises Approximately EUR 80 Million From Capital Measure
eqs_en 
0 30.08.22
DGAP-News: Heidelberg Pharma AG Launches Rights Issue of up to EUR 80 Million
DGAP-News: Heidelberg Pharma AG Launches Rights Issue of up to EUR 80 Million
DGAP-News: Heidelberg Pharma AG Launches Rights Issue of up to EUR 80 Million
eqs_en 
0 12.08.22
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Presents Preclinical Evidence of Combination Therapy Potential for Varoglutamstat in AD at AAIC 2022
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Presents Preclinical Evidence of Combination Therapy Potential for Varoglutamstat in AD at AAIC 2022
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Presents Preclinical Evidence of Combination Therapy Potential for Varoglutamstat in AD at AAIC 2022
eqs_en 
0 31.07.22
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Presents Key Phase 2b Data at AAIC 2022 Showing that Varoglutamstat is Well Tolerated at Doses with High Target Inhibition, Highlighting Unique O
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Presents Key Phase 2b Data at AAIC 2022 Showing that Varoglutamstat is Well Tolerated at Doses with High Target Inhibition, Highlighting Unique O
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Presents Key Phase 2b Data at AAIC 2022 Showing that Varoglutamstat is Well Tolerated at Doses with High Target Inhibition, Highlighting Unique O
eqs_en 
0 31.07.22
DGAP-Adhoc: Heidelberg Pharma and Chiome Bioscience Sign Exclusive, Target-Specific Research and Option Agreement for the Development of an Antibody Drug Conjugate
DGAP-Adhoc: Heidelberg Pharma and Chiome Bioscience Sign Exclusive, Target-Specific Research and Option Agreement for the Development of an Antibody Drug Conjugate
DGAP-Adhoc: Heidelberg Pharma and Chiome Bioscience Sign Exclusive, Target-Specific Research and Option Agreement for the Development of an Antibody Drug Conjugate
eqs_en 
0 13.07.22
DGAP-News: Heidelberg Pharma AG: Heidelberg Pharma Reports on First Half-Year 2022
DGAP-News: Heidelberg Pharma AG: Heidelberg Pharma Reports on First Half-Year 2022
DGAP-News: Heidelberg Pharma AG: Heidelberg Pharma Reports on First Half-Year 2022
eqs_en 
0 12.07.22
DGAP-News: Heidelberg Pharma Reports Outcome of the Annual General Meeting 2022
DGAP-News: Heidelberg Pharma Reports Outcome of the Annual General Meeting 2022
DGAP-News: Heidelberg Pharma Reports Outcome of the Annual General Meeting 2022
eqs_en 
0 28.06.22
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Positive Independent Data Safety Monitoring Board Recommendation for Phase 2b Study of Varoglutamstat in AD
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Positive Independent Data Safety Monitoring Board Recommendation for Phase 2b Study of Varoglutamstat in AD
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Positive Independent Data Safety Monitoring Board Recommendation for Phase 2b Study of Varoglutamstat in AD
eqs_en 
0 23.06.22
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Outcome of Annual General Meeting 2022
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Outcome of Annual General Meeting 2022
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Outcome of Annual General Meeting 2022
eqs_en 
0 22.06.22
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Q1 2022 Financial Results and Highlights Operational Progress
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Q1 2022 Financial Results and Highlights Operational Progress
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Q1 2022 Financial Results and Highlights Operational Progress
eqs_en 
0 15.06.22
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report First Quarter 2022 Financial Results on June 15, 2022
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report First Quarter 2022 Financial Results on June 15, 2022
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report First Quarter 2022 Financial Results on June 15, 2022
eqs_en 
0 08.06.22
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Hold its Annual General Meeting on June 22, 2022
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Hold its Annual General Meeting on June 22, 2022
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Hold its Annual General Meeting on June 22, 2022
eqs_en 
0 11.05.22
DGAP-Adhoc: Heidelberg Pharma AG and Partner Huadong Receive all Approvals for the Announced Transaction from the Authorities and Plan Capital Measure
DGAP-Adhoc: Heidelberg Pharma AG and Partner Huadong Receive all Approvals for the Announced Transaction from the Authorities and Plan Capital Measure
DGAP-Adhoc: Heidelberg Pharma AG and Partner Huadong Receive all Approvals for the Announced Transaction from the Authorities and Plan Capital Measure
eqs_en 
0 09.05.22
DGAP-News: Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2022
DGAP-News: Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2022
DGAP-News: Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2022
eqs_en 
0 28.04.22
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Full Year 2021 Financial Results and Highlights Operational Progress
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Full Year 2021 Financial Results and Highlights Operational Progress
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Full Year 2021 Financial Results and Highlights Operational Progress
eqs_en 
0 28.04.22
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report Full Year 2021 Financial Results and Operational Progress on April 28, 2022
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report Full Year 2021 Financial Results and Operational Progress on April 28, 2022
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report Full Year 2021 Financial Results and Operational Progress on April 28, 2022
eqs_en 
0 21.04.22
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Participate at Upcoming Investor Conferences
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Participate at Upcoming Investor Conferences
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Participate at Upcoming Investor Conferences
eqs_en 
0 20.04.22
DGAP-News: Bio-Gate AG erweitert Geschäftsfeld Dermakosmetik mit CBD-Produkten
DGAP-News: Bio-Gate AG erweitert Geschäftsfeld Dermakosmetik mit CBD-Produkten
DGAP-News: Bio-Gate AG erweitert Geschäftsfeld Dermakosmetik mit CBD-Produkten
eqs_de 
0 13.04.22